Longitudinal testing of hippocampal plasticity reveals the onset and maintenance of endogenous human Aß-induced synaptic dysfunction in individual freely behaving pre-plaque transgenic rats: Rapid reversal by anti-Aß agents

Acta Neuropathologica Communications

Volumn 2, Issue 1, 2014, Pages

  Qi, Yingjie ^a   Klyubin, Igor ^a   Harney, Sarah C ^a   Hu, NengWei ^a   Cullen, William K ^a   Grant, Marianne K ^b   Steffen, Julia ^e   Wilson, Edward N ^f   Do Carmo, Sonia ^f   Remy, Stefan ^e   Fuhrmann, Martin ^e   Ashe, Karen H ^b,c,d   Cuello, A Claudio ^f   Rowan, Michael J ^a  

^a TRINITY COLLEGE DUBLIN   (Ireland)

^b UNIVERSITY OF MINNESOTA   (United States)

^c UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

^e GERMAN CENTER FOR NEURODEGENERATIVE DISEASES DZNE   (Germany)

^f MCGILL UNIVERSITY   (Canada)

Author keywords

Alzheimer's disease; Amyloid ; Immunotherapy; Long term potentiation (LTP); Longitudinal; Secretase inhibitor; Transgenic rat

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; ANTIBODY; ASPARTIC PROTEINASE; BACE PROTEIN, RAT; FUSED HETEROCYCLIC RINGS; MRK 560; N-(3-(2-AMINO-4A,5,7,7A-TETRAHYDRO-4H-FURO(3,4-D)(1,3)THIAZIN-7A-YL)-4-FLUOROPHENYL)-5-FLUOROPICOLINAMIDE; PICOLINIC ACID DERIVATIVE; SECRETASE; SULFONAMIDE;

AGE; ALZHEIMER DISEASE; ANIMAL; ANIMAL BEHAVIOR; ANTAGONISTS AND INHIBITORS; DISEASE MODEL; DRUG EFFECTS; GENETICS; HIPPOCAMPUS; HUMAN; IMMUNOLOGY; LONG TERM POTENTIATION; MALE; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY; RAT; SYNAPTIC TRANSMISSION; TRANSGENIC RAT; WISTAR RAT;

AGE FACTORS; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; AMYLOID BETA-PROTEIN PRECURSOR; AMYLOID PRECURSOR PROTEIN SECRETASES; ANIMALS; ANTIBODIES; ASPARTIC ACID ENDOPEPTIDASES; BEHAVIOR, ANIMAL; DISEASE MODELS, ANIMAL; HETEROCYCLIC COMPOUNDS, 2-RING; HIPPOCAMPUS; HUMANS; LONG-TERM POTENTIATION; MALE; PICOLINIC ACIDS; RATS; RATS, TRANSGENIC; RATS, WISTAR; SULFONAMIDES; SYNAPTIC TRANSMISSION;

EID: 84965086893     PISSN: None     EISSN: 20515960     Source Type: Journal    
DOI: 10.1186/s40478-014-0175-x     Document Type: Article

References (53)

1. Dubois B, Feldman HH, Jacova C, Hampel H, Molinuevo JL, Blennow K, DeKosky ST, Gauthier S, Selkoe D, Bateman R, Cappa S, Crutch S, Engelborghs S, Frisoni GB, Fox NC, Galasko D, Habert MO, Jicha GA, Nordberg A, Pasquier F, Rabinovici G, Robert P, Rowe C, Salloway S, Sarazin M, Epelbaum S, de Souza LC, Vellas B, Visser PJ, Schneider L: Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria. Lancet Neurol 2014, 13: 614-629. doi10.1016/S1474-4422(14)70090-0 10.1016/S1474-4422(14)70090-0
2. Mucke L, Selkoe DJ: Neurotoxicity of amyloid beta-protein: synaptic and network dysfunction. Cold Spring Harb Perspect Med 2012, 2: a006338. doi10.1101/cshperspect.a006338 10.1101/cshperspect.a006338
3. Klyubin I, Cullen WK, Hu NW, Rowan MJ: Alzheimer's disease Abeta assemblies mediating rapid disruption of synaptic plasticity and memory. Mol Brain 2012, 5: 25. doi10.1186/1756-6606-5-25 10.1186/1756-6606-5-25
4. Klyubin I, Ondrejcak T, Hayes J, Cullen WK, Mably AJ, Walsh DM, Rowan MJ: Neurotransmitter receptor and time dependence of the synaptic plasticity disrupting actions of Alzheimer's disease Abeta in vivo. Philos Trans R Soc Lond Ser B Biol Sci 2014, 369: 20130147. doi10.1098/rstb.2013.0147 10.1098/rstb.2013.0147
5. Nistico R, Pignatelli M, Piccinin S, Mercuri NB, Collingridge G: Targeting synaptic dysfunction in Alzheimer's disease therapy. Mol Neurobiol 2012, 46: 572-587. doi 10.1007/s12035-012-8324-3 10.1007/s12035-012-8324-3
6. Randall AD, Witton J, Booth C, Hynes-Allen A, Brown JT: The functional neurophysiology of the amyloid precursor protein (APP) processing pathway. Neuropharmacology 2010, 59: 243-267. doi10.1016/j.neuropharm.2010.02.011 10.1016/j.neuropharm.2010.02.011
7. Do Carmo S, Cuello AC: Modeling Alzheimer's disease in transgenic rats. Mol Neurodegener 2013, 8: 37. doi 10.1186/1750-1326-8-37 10.1186/1750-1326-8-37
8. Galeano P, Martino Adami PV, Do Carmo S, Blanco E, Rotondaro C, Capani F, Castano EM, Cuello AC, Morelli L: Longitudinal analysis of the behavioral phenotype in a novel transgenic rat model of early stages of Alzheimer's disease. Front Behav Neurosci 2014, 8: 321. doi10.3389/fnbeh.2014.00321 10.3389/fnbeh.2014.00321
9. Hanzel CE, Pichet-Binette A, Pimentel LS, Iulita MF, Allard S, Ducatenzeiler A, Do Carmo S, Cuello AC: Neuronal driven pre-plaque inflammation in a transgenic rat model of Alzheimer's disease. Neurobiol Aging 2014, 35: 2249-2262. doi10.1016/j.neurobiolaging.2014.03.026 10.1016/j.neurobiolaging.2014.03.026
10. Iulita MF, Allard S, Richter L, Munter LM, Ducatenzeiler A, Weise C, Do Carmo S, Klein WL, Multhaup G, Cuello AC: Intracellular Abeta pathology and early cognitive impairments in a transgenic rat overexpressing human amyloid precursor protein: a multidimensional study. Acta Neuropathol Commun 2014, 2: 61. doi 10.1186/2051-5960-2-61 10.1186/2051-5960-2-61
11. Leon WC, Canneva F, Partridge V, Allard S, Ferretti MT, DeWilde A, Vercauteren F, Atifeh R, Ducatenzeiler A, Klein W, Szyf M, Alhonen L, Cuello AC: A novel transgenic rat model with a full Alzheimer's-like amyloid pathology displays pre-plaque intracellular amyloid-beta-associated cognitive impairment. J Alzheimers Dis 2010, 20: 113-126. doi10.3233/JAD-2010-1349
12. Cullen WK, Suh YH, Anwyl R, Rowan MJ: Block of LTP in rat hippocampus in vivo by ß-amyloid precursor protein fragments. Neuroreport 1997, 8: 3213-3217. 10.1097/00001756-199710200-00006
13. Qi Y, Hu NW, Rowan MJ: Switching off LTP: mGlu and NMDA receptor-dependent novelty exploration-induced depotentiation in the rat hippocampus. Cereb Cortex 2013, 23: 932-939. doi10.1093/cercor/bhs086 10.1093/cercor/bhs086
14. Ryan BK, Vollmayr B, Klyubin I, Gass P, Rowan MJ: Persistent inhibition of hippocampal long-term potentiation in vivo by learned helplessness stress. Hippocampus 2010, 20: 758-767. doi10.1002/hipo.20677 10.1002/hipo.20677
15. Lesne S, Koh MT, Kotilinek L, Kayed R, Glabe CG, Yang A, Gallagher M, Ashe KH: A specific amyloid-beta protein assembly in the brain impairs memory. Nature 2006, 440: 352-357. doi10.1038/nature04533 10.1038/nature04533
16. Grant SM, Ducatenzeiler A, Szyf M, Cuello AC: Abeta immunoreactive material is present in several intracellular compartments in transfected, neuronally differentiated, P19 cells expressing the human amyloid beta-protein precursor. J Alzheimers Dis 2000, 2: 207-222.
17. Adekar SP, Jones RM, Elias MD, Al-Saleem FH, Root MJ, Simpson LL, Dessain SK: Hybridoma populations enriched for affinity-matured human IgGs yield high-affinity antibodies specific for botulinum neurotoxins. J Immunol Methods 2008, 333: 156-166. doi10.1016/j.jim.2008.01.015 10.1016/j.jim.2008.01.015
18. Fowler SW, Chiang AC, Savjani RR, Larson ME, Sherman MA, Schuler DR, Cirrito JR, Lesne SE, Jankowsky JL: Genetic modulation of soluble Abeta rescues cognitive and synaptic impairment in a mouse model of Alzheimer's disease. J Neurosci 2014, 34: 7871-7885. doi10.1523/JNEUROSCI.0572-14.2014 10.1523/JNEUROSCI.0572-14.2014
19. Handoko M, Grant M, Kuskowski M, Zahs KR, Wallin A, Blennow K, Ashe KH: Correlation of specific amyloid-beta oligomers with tau in cerebrospinal fluid from cognitively normal older adults. JAMA Neurol 2013, 70: 594-599. doi10.1001/jamaneurol.2013.48 10.1001/jamaneurol.2013.48
20. Doyle C, Holscher C, Rowan MJ, Anwyl R: The selective neuronal NO synthase inhibitor 7-nitro-indazole blocks both long-term potentiation and depotentiation of field EPSPs in rat hippocampal CA1 in vivo. J Neurosci 1996, 16: 418-424.
21. Hu NW, Smith IM, Walsh DM, Rowan MJ: Soluble amyloid-beta peptides potently disrupt hippocampal synaptic plasticity in the absence of cerebrovascular dysfunction in vivo. Brain 2008, 131: 2414-2424. 10.1093/brain/awn174
22. Blanpied TA, Berger TW: Characterization in vivo of the NMDA receptor-mediated component of dentate granule cell population synaptic responses to perforant path input. Hippocampus 1992, 2: 373-388. doi10.1002/hipo.450020405 10.1002/hipo.450020405
23. Grienberger C, Chen X, Konnerth A: NMDA receptor-dependent multidendrite Ca(2+) spikes required for hippocampal burst firing in vivo. Neuron 2014, 81: 1274-1281. doi10.1016/j.neuron.2014.01.014 10.1016/j.neuron.2014.01.014
24. Anwyl R, Mulkeen D, Rowan MJ: The role of N-methyl-D-aspartate receptors in the generation of short-term potentiation in the rat hippocampus. Brain Res 1989, 503: 148-151. 10.1016/0006-8993(89)91716-2
25. Park P, Volianskis A, Sanderson TM, Bortolotto ZA, Jane DE, Zhuo M, Kaang BK, Collingridge GL: NMDA receptor-dependent long-term potentiation comprises a family of temporally overlapping forms of synaptic plasticity that are induced by different patterns of stimulation. Philos Trans R Soc Lond Ser B Biol Sci 2014, 369: 20130131. doi10.1098/rstb.2013.0131 10.1098/rstb.2013.0131
26. Shipton OA, Paulsen O: GluN2A and GluN2B subunit-containing NMDA receptors in hippocampal plasticity. Philos Trans R Soc Lond Ser B Biol Sci 2014, 369: 20130163. doi10.1098/rstb.2013.0163 10.1098/rstb.2013.0163
27. May P, Boggs L, Brier R, Calligaro D, Citron M, Day T, Lin S, Lindstrom T, Mergott D, Monk S, Sanchez-Felix MV, Sheehan S, Vaught G, Yang Z, Audia J Preclinical characterization of LY2886721: A BACE1 inhibitor in clinical development for early Alzheimer's disease. Alzheimer's & Dementia: The Journal of the Alzheimer's Association 8: P95 doi10.1016/j.jalz.2012.05.235
28. Kervern M, Angeli A, Nicole O, Leveille F, Parent B, Villette V, Buisson A, Dutar P: Selective impairment of some forms of synaptic plasticity by oligomeric amyloid-beta peptide in the mouse hippocampus: implication of extrasynaptic NMDA receptors. J Alzheimers Dis 2012, 32: 183-196. doi10.3233/JAD-2012-120394
29. Raymond CR, Ireland DR, Abraham WC: NMDA receptor regulation by amyloid-beta does not account for its inhibition of LTP in rat hippocampus. Brain Res 2003, 968: 263-272. 10.1016/S0006-8993(03)02269-8
30. Ryan BK, Anwyl R, Rowan MJ: 5-HT2 receptor-mediated reversal of the inhibition of hippocampal long-term potentiation by acute inescapable stress. Neuropharmacology 2008, 55: 175-182. doi10.1016/j.neuropharm.2008.05.006 10.1016/j.neuropharm.2008.05.006
31. Davis KE, Fox S, Gigg J: Increased hippocampal excitability in the 3xTgAD mouse model for Alzheimer's disease in vivo. PLoS One 2014, 9: e91203. doi 10.1371/journal.pone.0091203 10.1371/journal.pone.0091203
32. Gruart A, Lopez-Ramos JC, Munoz MD, Delgado-Garcia JM: Aged wild-type and APP, PS1, and APP + PS1 mice present similar deficits in associative learning and synaptic plasticity independent of amyloid load. Neurobiol Dis 2008, 30: 439-450. doi10.1016/j.nbd.2008.03.001 10.1016/j.nbd.2008.03.001
33. Mitchell JC, Ariff BB, Yates DM, Lau KF, Perkinton MS, Rogelj B, Stephenson JD, Miller CC, McLoughlin DM: X11beta rescues memory and long-term potentiation deficits in Alzheimer's disease APPswe Tg2576 mice. Hum Mol Genet 2009, 18: 4492-4500. doi 10.1093/hmg/ddp408 10.1093/hmg/ddp408
34. Townsend M, Qu Y, Gray A, Wu Z, Seto T, Hutton M, Shearman MS, Middleton RE: Oral treatment with a gamma-secretase inhibitor improves long-term potentiation in a mouse model of Alzheimer's disease. J Pharmacol Exp Ther 2010, 333: 110-119. doi 10.1124/jpet.109.163691 10.1124/jpet.109.163691
35. Liu L, Orozco IJ, Planel E, Wen Y, Bretteville A, Krishnamurthy P, Wang L, Herman M, Figueroa H, Yu WH, Arancio O, Duff K: A transgenic rat that develops Alzheimer's disease-like amyloid pathology, deficits in synaptic plasticity and cognitive impairment. Neurobiol Dis 2008, 31: 46-57. doi10.1016/j.nbd.2008.03.005 10.1016/j.nbd.2008.03.005
36. Cisse M, Halabisky B, Harris J, Devidze N, Dubal DB, Sun B, Orr A, Lotz G, Kim DH, Hamto P, Ho K, Yu GQ, Mucke L: Reversing EphB2 depletion rescues cognitive functions in Alzheimer model. Nature 2011, 469: 47-52. doi10.1038/nature09635 10.1038/nature09635
37. Dewachter I, Filipkowski RK, Priller C, Ris L, Neyton J, Croes S, Terwel D, Gysemans M, Devijver H, Borghgraef P, Godaux E, Kaczmarek L, Herms J, Van Leuven F: Deregulation of NMDA-receptor function and down-stream signaling in APP[V717I] transgenic mice. Neurobiol Aging 2009, 30: 241-256. doi10.1016/j.neurobiolaging.2007.06.011 10.1016/j.neurobiolaging.2007.06.011
38. Tozzi A, Sclip A, Tantucci M, de Iure A, Ghiglieri V, Costa C, Di Filippo M, Borsello T, Calabresi P (2014) Region- and age-dependent reductions of hippocampal long-term potentiation and NMDA to AMPA ratio in a genetic model of Alzheimer's disease. Neurobiology of aging: doi10.1016/j.neurobiolaging.2014.07.002
39. Wang Y, Mattson MP: L-type Ca2+ currents at CA1 synapses, but not CA3 or dentate granule neuron synapses, are increased in 3xTgAD mice in an age-dependent manner. Neurobiol Aging 2014, 35: 88-95. doi10.1016/j.neurobiolaging.2013.07.007 10.1016/j.neurobiolaging.2013.07.007
40. Snyder EM, Nong Y, Almeida CG, Paul S, Moran T, Choi EY, Nairn AC, Salter MW, Lombroso PJ, Gouras GK, Greengard P: Regulation of NMDA receptor trafficking by amyloid-beta. Nat Neurosci 2005, 8: 1051-1058. doi10.1038/nn1503 10.1038/nn1503
41. Wang HY, Lee DH, D'Andrea MR, Peterson PA, Shank RP, Reitz AB: beta-Amyloid(1-42) binds to alpha7 nicotinic acetylcholine receptor with high affinity. Implications for Alzheimer's disease pathology. J Biol Chem 2000, 275: 5626-5632. 10.1074/jbc.275.8.5626
42. Lauren J, Gimbel DA, Nygaard HB, Gilbert JW, Strittmatter SM: Cellular prion protein mediates impairment of synaptic plasticity by amyloid-beta oligomers. Nature 2009, 457: 1128-1132. doi nature07761 10.1038/nature07761
43. Um JW, Nygaard HB, Heiss JK, Kostylev MA, Stagi M, Vortmeyer A, Wisniewski T, Gunther EC, Strittmatter SM: Alzheimer amyloid-beta oligomer bound to postsynaptic prion protein activates Fyn to impair neurons. Nat Neurosci 2012, 15: 1227-1235. doi10.1038/nn.3178 10.1038/nn.3178
44. Hu NW, Klyubin I, Anwyl R, Rowan MJ: GluN2B subunit-containing NMDA receptor antagonists prevent Abeta-mediated synaptic plasticity disruption in vivo. Proc Natl Acad Sci U S A 2009, 106: 20504-20509. 10.1073/pnas.0908083106
45. Li S, Jin M, Koeglsperger T, Shepardson NE, Shankar GM, Selkoe DJ: Soluble Abeta oligomers inhibit long-term potentiation through a mechanism involving excessive activation of extrasynaptic NR2B-containing NMDA receptors. J Neurosci 2011, 31: 6627-6638. doi 10.1523/JNEUROSCI.0203-11.2011 10.1523/JNEUROSCI.0203-11.2011
46. Ronicke R, Mikhaylova M, Ronicke S, Meinhardt J, Schroder UH, Fandrich M, Reiser G, Kreutz MR, Reymann KG: Early neuronal dysfunction by amyloid beta oligomers depends on activation of NR2B-containing NMDA receptors. Neurobiol Aging 2011, 32: 2219-2228. doi10.1016/j.neurobiolaging.2010.01.011 10.1016/j.neurobiolaging.2010.01.011
47. Lesne SE, Sherman MA, Grant M, Kuskowski M, Schneider JA, Bennett DA, Ashe KH: Brain amyloid-beta oligomers in ageing and Alzheimer's disease. Brain 2013, 136: 1383-1398. doi10.1093/brain/awt062 10.1093/brain/awt062
48. Melnikova T, Fromholt S, Kim H, Lee D, Xu G, Price A, Moore BD, Golde TE, Felsenstein KM, Savonenko A, Borchelt DR: Reversible pathologic and cognitive phenotypes in an inducible model of Alzheimer-amyloidosis. J Neurosci 2013, 33: 3765-3779. doi10.1523/JNEUROSCI.4251-12.2013 10.1523/JNEUROSCI.4251-12.2013
49. Yang T, Hong S, O'Malley T, Sperling RA, Walsh DM, Selkoe DJ: New ELISAs with high specificity for soluble oligomers of amyloid beta-protein detect natural Abeta oligomers in human brain but not CSF. Alzheimers Dement 2013, 9: 99-112. doi10.1016/j.jalz.2012.11.005 10.1016/j.jalz.2012.11.005
50. Dodart JC, Bales KR, Gannon KS, Greene SJ, DeMattos RB, Mathis C, DeLong CA, Wu S, Wu X, Holtzman DM, Paul SM: Immunization reverses memory deficits without reducing brain Abeta burden in Alzheimer's disease model. Nat Neurosci 2002, 5: 452-457. doi10.1038/nn842
51. Kotilinek LA, Bacskai B, Westerman M, Kawarabayashi T, Younkin L, Hyman BT, Younkin S, Ashe KH: Reversible memory loss in a mouse transgenic model of Alzheimer's disease. J Neurosci 2002, 22: 6331-6335. doi20026675
52. Fukumoto H, Takahashi H, Tarui N, Matsui J, Tomita T, Hirode M, Sagayama M, Maeda R, Kawamoto M, Hirai K, Terauchi J, Sakura Y, Kakihana M, Kato K, Iwatsubo T, Miyamoto M: A noncompetitive BACE1 inhibitor TAK-070 ameliorates Abeta pathology and behavioral deficits in a mouse model of Alzheimer's disease. J Neurosci 2010, 30: 11157-11166. doi10.1523/JNEUROSCI.2884-10.2010 10.1523/JNEUROSCI.2884-10.2010
53. Comery TA, Martone RL, Aschmies S, Atchison KP, Diamantidis G, Gong X, Zhou H, Kreft AF, Pangalos MN, Sonnenberg-Reines J, Jacobsen JS, Marquis KL: Acute gamma-secretase inhibition improves contextual fear conditioning in the Tg2576 mouse model of Alzheimer's disease. J Neurosci 2005, 25: 8898-8902. doi10.1523/JNEUROSCI.2693-05.2005 10.1523/JNEUROSCI.2693-05.2005